Correlation Between KB Financial and Adaptimmune Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both KB Financial and Adaptimmune Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining KB Financial and Adaptimmune Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between KB Financial Group and Adaptimmune Therapeutics Plc, you can compare the effects of market volatilities on KB Financial and Adaptimmune Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in KB Financial with a short position of Adaptimmune Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of KB Financial and Adaptimmune Therapeutics.

Diversification Opportunities for KB Financial and Adaptimmune Therapeutics

-0.64
  Correlation Coefficient

Excellent diversification

The 3 months correlation between KB Financial and Adaptimmune is -0.64. Overlapping area represents the amount of risk that can be diversified away by holding KB Financial Group and Adaptimmune Therapeutics Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptimmune Therapeutics and KB Financial is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on KB Financial Group are associated (or correlated) with Adaptimmune Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptimmune Therapeutics has no effect on the direction of KB Financial i.e., KB Financial and Adaptimmune Therapeutics go up and down completely randomly.

Pair Corralation between KB Financial and Adaptimmune Therapeutics

Allowing for the 90-day total investment horizon KB Financial Group is expected to generate 0.52 times more return on investment than Adaptimmune Therapeutics. However, KB Financial Group is 1.93 times less risky than Adaptimmune Therapeutics. It trades about 0.08 of its potential returns per unit of risk. Adaptimmune Therapeutics Plc is currently generating about -0.15 per unit of risk. If you would invest  6,367  in KB Financial Group on August 31, 2024 and sell it today you would earn a total of  712.00  from holding KB Financial Group or generate 11.18% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

KB Financial Group  vs.  Adaptimmune Therapeutics Plc

 Performance 
       Timeline  
KB Financial Group 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in KB Financial Group are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat fragile fundamental drivers, KB Financial may actually be approaching a critical reversion point that can send shares even higher in December 2024.
Adaptimmune Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

KB Financial and Adaptimmune Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with KB Financial and Adaptimmune Therapeutics

The main advantage of trading using opposite KB Financial and Adaptimmune Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if KB Financial position performs unexpectedly, Adaptimmune Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will offset losses from the drop in Adaptimmune Therapeutics' long position.
The idea behind KB Financial Group and Adaptimmune Therapeutics Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years